Is there any difference between Gilteritinib in Laos and ASEAN?

Laos Daxiong and ASEAN are different manufacturers in Laos. It is understood that the generic version of Gilteritinib produced by Laos Daxiong and ASEAN Pharmaceuticals is on the market. Its pharmaceutical ingredients are basically the same as those of the original Gilteritinib. The difference may be different prices and specifications. The price of each box of 40mg*84 tablets may be around RMB 4,000 (the price may fluctuate due to exchange rates). Giritinibis an oral, potent, selective FLT3 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations with single-agent activity.

Acute myeloid leukemia (AML) is an aggressive cancer that affects the body's bone marrow and blood, and the incidence of the disease may increase with age. Before patients are treated with this drug, doctors will choose to treat it with gilitinib based on the presence of FLT3 mutations in the blood or bone marrow. The recommended dose is 120 mg, once daily. In the absence of disease progression or unacceptable toxicity, patients need to be treated for at least 6 months to allow time for clinical response.

The original drug of geritinib is currently on the market in China and has not yet been included in medical insurance. The price of each box of 40mg*42 tablets is around RMB 25,000-70,000. It is expensive and may not be affordable for families with heavy financial burdens. The price of the Hong Kong version of the original drug, 40mg*42 tablets per box, is around RMB 90,000, and the price of the European version, 40mg*84 tablets per box, is around RMB 210,000 (prices may fluctuate due to exchange rates). For specific prices and drug details, please consult Yaode’s medical consultant.